MARK2 and neoplasm: Dabrafenib and trametinib are targeted drugs targeting BRAF and MEK1/2 belonging to the serine/threonine kinase family of the RAS pathway, respectively, which inhibit tumor cell proliferation by blocking the RAF-MEK-ERK signaling pathway.